Meag Munich Ergo Kapitalanlagegesellschaft MBH cut its holdings in shares of UnitedHealth Group Inc (NYSE:UNH) by 55.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,080 shares of the healthcare conglomerate’s stock after selling 128,653 shares during the quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in UnitedHealth Group were worth $20,080,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Chip Partners Inc. acquired a new stake in UnitedHealth Group during the second quarter worth about $110,000. Bruderman Asset Management LLC acquired a new stake in shares of UnitedHealth Group in the second quarter valued at about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of UnitedHealth Group by 433.3% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock valued at $119,000 after buying an additional 520 shares in the last quarter. BDO Wealth Advisors LLC acquired a new stake in shares of UnitedHealth Group in the second quarter valued at about $121,000. Finally, Acrospire Investment Management LLC grew its stake in shares of UnitedHealth Group by 130.7% in the second quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock valued at $131,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 86.21% of the company’s stock.
In related news, Director Gail R. Wilensky sold 5,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total value of $1,250,536.00. Following the sale, the director now directly owns 61,137 shares in the company, valued at approximately $13,652,503.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kenneth Irwin Shine sold 457 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $211.03, for a total value of $96,440.71. The disclosure for this sale can be found here. In the last three months, insiders sold 53,853 shares of company stock worth $12,358,508. Company insiders own 0.89% of the company’s stock.
Shares of UnitedHealth Group Inc (UNH) traded down $1.56 during midday trading on Thursday, hitting $235.22. The company had a trading volume of 4,267,101 shares, compared to its average volume of 3,420,000. The company has a market cap of $227,420.00, a P/E ratio of 21.96, a price-to-earnings-growth ratio of 1.38 and a beta of 0.66. UnitedHealth Group Inc has a 1-year low of $156.49 and a 1-year high of $250.79. The company has a current ratio of 0.73, a quick ratio of 0.70 and a debt-to-equity ratio of 0.58.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.09. The business had revenue of $52.06 billion for the quarter, compared to the consensus estimate of $51.57 billion. UnitedHealth Group had a return on equity of 21.29% and a net margin of 5.25%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $2.11 EPS. equities research analysts forecast that UnitedHealth Group Inc will post 12.51 earnings per share for the current year.
A number of research firms have recently issued reports on UNH. Piper Jaffray Companies reiterated a “buy” rating and issued a $259.00 target price on shares of UnitedHealth Group in a research note on Wednesday, January 17th. Oppenheimer increased their target price on UnitedHealth Group from $260.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th. Citigroup raised their price objective on UnitedHealth Group from $235.00 to $268.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald restated a “buy” rating and set a $208.00 price objective on shares of UnitedHealth Group in a research note on Tuesday, October 17th. Finally, Royal Bank of Canada raised their price objective on UnitedHealth Group from $269.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th. Two research analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $243.22.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/01/unitedhealth-group-inc-unh-shares-sold-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.